<u>La Renon</u>



Reignite the spark of

CONTROL

with

LOBELONG

Lobeglitazone Sulfate Tablets 0.5 mg

LOBELONG

Lobeglitazone Sulfate Tablets 0.5 mg

Description

LOBELONG contains lobeglitazone as an active ingredient and is available as a tablet in a strength of 0.5 mg. Lobeglitazone is a novel thiazolidinedione with potent efficacy and a favorable safety profile.

Indication

Indicated for treatment of adult type 2 diabetes mellitus patients:

- **As Monotherapy:** Who are inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
- As Dual Oral Therapy in Combination with:
- → Who are inadequately controlled by diet and exercise for whom metformin despite maximal tolerated dose of metformin therapy.
- → Who are inadequately controlled by diet and exercise and taking a sulphonylurea at maximal tolerated dose of sulphonylurea monotherapy in which metformin is inappropriate because of contraindications or intolerance.

Mechanism of Action

- Lobeglitazone acts as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells.
- By promoting the binding of insulin at fat cells, lobeglitazone has been shown to reduce blood sugar levels, lower Hemoglobin A1C (HbA1C) levels, and improve lipid and liver profiles.

Dosage and administration

• Lobeglitazone alone or in combination is administered at a dose of 0.5 mg once a day and can be taken with or without food.

Presentation

LOBELONG is available as a strip of 10 tablets.



Prescribing Information

La Renon Healthcare Private Limited